Search

Search results

399 results found

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

Langley, Richard G, Steven R Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu, Jean-Paul Ortonne, Kenneth B Gordon, and Alexa B Kimball. 2010. “Ustekinumab Significantly Improves Symptoms of Anxiety, Depression, and Skin-Related Quality of Life in Patients With Moderate-to-Severe Psoriasis: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Trial.”. Journal of the American Academy of Dermatology 63 (3): 457-65.

Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial.

Zhu, B, E Edson-Heredia, J Guo, T Maeda-Chubachi, W Shen, and A B Kimball. 2014. “Itching Is a Significant Problem and a Mediator Between Disease Severity and Quality of Life for Patients With Psoriasis: Results from a Randomized Controlled Trial.”. The British Journal of Dermatology 171 (5): 1215-9.

Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Shear, N H, R Alhusayen, A Fernandez-Obregon, A B Kimball, A Menter, J J Wu, K Goyal, H Patel, R Lin, and A W Armstrong. 2017. “Observations from Our Evaluation of Bodyweight Changes After Initiation of a Biologic Therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).”. Journal of the European Academy of Dermatology and Venereology : JEADV 31 (12): e544-e547.